1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells by unknown
1,25-Dihydroxyvitamin D 3-induced Differentiation
in a Human Promyelocytic Leukemia Cell Line (HL-60):
Receptor-mediated Maturation to Macrophage-like Cells
DAVID J . MANGELSDORF, H . PHILLIP KOEFFLER, CAROL A. DONALDSON,
J. WESLEY PIKE, and MARK R. HAUSSLER
Department of Biochemistry, University of Arizona Health Sciences Center, Tucson, Arizona 85724; and
Department of Medicine, University of California School of Medicine, Los Angeles, California 90024
ABSTRACT The human-derived promyelocytic leukemia cell line, HL-60, is known to differ-
entiate into mature myeloid cells in the presence of 1,25-dihydroxyvitamin D3 (1,25[OH]2D3).
We investigated differentiation by monitoring 1,25(OH)2D3-exposed HL-60 cells for phagocytic
activity, ability to reduce nitroblue tetrazolium, binding of the chemotaxin N-formyl-methionyl-
leucyl-[3H]phenylalanine, development of nonspecific acid esterase activity, and morpholog-
ical maturation of Wright-Giemsa-stained cells. 1,25(OH)2D3 concentrations as low as 10-'0
M caused significant development of phagocytosis, nitroblue tetrazolium reduction, and the
emergence of differentiated myeloid cells that had morphological characteristics of both
metamyelocytes and monocytes. These cells were conclusively identified as monocytes/
macrophages based upon their adherence to the plastic flasks and their content of the
macrophage-characteristic nonspecific acid esterase enzyme. The estimated ED50 for
1,25(OH)2D3-induced differentiation based upon nitroblue tetrazolium reduction and N-
formyl-methionyl-leucyl-[3H]phenylalanine binding was 5.7 x 10-9 M. HL-60 cells exhibited
a complex growth response with various levels of 1,25(OH)2D3: :510-1' M had no detectable
effect, 10-9 M stimulated growth, and 2:10-8 M sharply inhibited proliferation. We also
detected and quantitated the specific receptor for 1,25(OH)2D3 in HL-60 and HL-60 Blast, a
sub-clone resistant to the growth and differentiation effects of 1,25(OH)2D3. The receptor in
both lines was characterized as a DNA-binding protein that migrated at 3.3S on high-salt
sucrose gradients. Unequivocal identification was provided by selective dissociation of the
1,25(OH)2D3-receptor complex with the mercurial reagent, p-chloromercuribenzenesulfonic
acid, and by a shift in its sedimentation position upon complexing with anti-receptor mono-
clonal antibody. On the basis of labeling of whole cells with 1,25(OH)2[3H]D3 in culture, we
found that HL-60 contains 4,000 1,25(OH)2D3 receptor molecules per cell, while the
nonresponsive HL-60 Blast is endowed with -8% of that number. The concentration of
1,25(OH)2D3 (5 x 10-9 M) in complete culture medium, which facilitates the saturation of
receptors in HL-60 cells, is virtually identical to the ED50 for the sterol's induction of
differentiation. This correspondence, plus the resistance of the relatively receptor-poor HL-
60 Blast, indicates that 1,25(OH)2D3-induced differentiation of HL-60 cells to monocytes/
macrophages is occurring via receptor-mediated events.
The induced differentiation ofthehuman promyelocytic leu-
￿
tamin D3 (1,25(OH]2D3), is of great current interest (1-4).
kemia, HL-60, by a variety of compounds such as phorbol
￿
The most potent inducer of differentiation in HL-60 cells is
esters, DMSO, retinoic acid (RA),' and la,25-dihydroxyvi-
various concentrations of KCI; NBT, nitroblue tetrazolium; PBS,
'Abbreviations used in this paper: FMLP, N-formyl-methionyl-leu-
￿
phosphate-buffered saline; PCMBS, p-chloromercuribenzene sulfonic
cyl-phenylalanine;KET, IrnM EDTA, 10 mM Tris-HCI, pH 7.4, and
￿
acid; RA, retinoic acid; 1,25(OH)ZD3, 1,25-dihydroxyvitaminD3.
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effective at nanomolar concentrations and is reported to elicit
differentiation along the granulocyte pathway (4). The poten-
tial physiologic significance of 1,25(OH)2D3-mediated differ-
entiation of myeloid cells to granulocytes is unknown. Fur-
thermore, 1,25(OH)2D3 similarly causes the differentiation of
the murine myeloid leukemia M 1 cell line to macrophages in
culture (5). The pharmacologic utility of 1,25(OH)2D3 in this
latter process is demonstrated by its capacity to prolong the
survival time of mice inoculated with M1 cells, in vivo (6).
The role of 1,25(OH)2D3as an agent responsible for mineral
homeostasis has been extensively studied (7). Its mechanism
of action within target cells is apparently steroid hormone-
like, in that 1,25(OH)2D3first binds to a specific, high affinity
cytosolic receptor protein which then translocates into the
nucleus, binds to chromatin (8), and consequently initiates
genomic expression of the necessary mineral-regulating pro-
teins (9). In support of this theory are the findings that all
known 1,25(OH)2D3-responsive tissues such as the intestine
(10), bone (11), and kidney (12), contain the cytosolic recep-
tor. In addition, many other tissues and cultured cells have
been shown to possess 1,25(OH)2D3 receptors (13, 14), in-
cluding some tumor cells (14-18).
In contrast to the current progress achieved in elucidating
the role of 1,25(OH)2D3 in mineral metabolism, its mecha-
nism of action and biological significance in the differentia-
tion of HL-60 cells are unknown. Preliminary evidence by
Tanaka et al. (19) implicates the presence of cytosolic
1,25(OH)2D3 receptors and suggests that differentiation may
be occurring by a mechanism similar to that of 1,25(OH)2D3'S
classical steroid hormone action. However, Tanaka et al. (19)
provided little direct physical and chemical identification of
the 1,25(OH)zD3 receptor protein in HL-60 cells. To further
investigate 1,25(OH)2D3-induced differentiation and the po-
tential role of the receptor, we compared the effects of
1,25(OH)2D3 on HL-60 and HL-60 Blast (a subclone of the
HL-60 parent line incapable ofdifferentiation), using a variety
of biological and biochemical differentiation parameters. In
accord with the preliminary data of Bar-Shavit et al. (20), but
in contrast to the findings of Miyaura et al. (4), we show that
1,25(OH)2D3 induces HL-60 (but not HL-60 Blast) to differ-
entiate to monocytes and macrophages, and extensively de-
scribe this phenomenon. We also report the unqualified iden-
tification of the 1,25(OH)2D3 receptor in HL60 cells and the
existence of a positive correlation between 1,25(OH)2D3-in-
duced differentiation and the occurrence of occupied
1,25(OH)2D3 receptors.
MATERIALS AND METHODS
Materials: la,25-Dihydroxy(23,24[n]-'H)vitamin D3 (120 Ci/mmol)
was generated from 25-hydroxy(23,24fn]-3H)vitamin D3 (Amersham Corp.,
Arlington Heights, IL) as described (21). Nonradioactive 1,25(OH)2D3 was a
giftofDr. Milan Uskokovic ofHoffmann-LaRoche(Nutley, NJ). DNA(Worth-
ington Biochemical Corp., Freehold, NJ) andcellulose (Cellex N-I, Bio-Rad
Laboratories, Richmond, CA)were coupled by amodification ofthe procedure
ofAlberts andHerrick (22). Formyl-L-methionyl-L-leucyl-t,-phenylalanine, N-
[phenylalanine-ring-2,6'H(N)]-(['H]FMLP, 60 Ci/mmol) was secured from
NewEngland Nuclear (Boston, MA). Nonradioactive FMLP, pchloromercu-
ribenzene sulfonic acid (PCMBS), all-trans-retinoic acid (RA), and bovine
serum albumin were purchased from Sigma Chemical Co. (St. Loius, MO).
DMSOwaspurchased from Fischer ScientificCo. (Fairlawn, NJ) and ultrapure
sucrose from Bethesda Research Laboratories (Rockville, MD). WhatmanDE-
81 filters are DEAE anion exchange filtersobtained from Reeve Angel (Clifton,
NJ). All other chemicals were ofreagentgrade or better.
Buffers:
￿
The following buffers were used: PBS (Dulbecco's phosphate-
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buffered saline), HPB(0.01 MTris-HCI, pH 7.5, 2 mM EDTA, 0.5 mM EGTA,
0.15 mM spermine, 0.5 mM spermidine, 5 mM dithiothreitol, and KET (1
mM EDTA, 10 mM Tris-HCl, pH 7.4, and various concentrations ofKCI; e.g.
KET-0. I = 0.1 M KClin KET).
Cells:
￿
HL-60 (23), a continuous human myeloid cell line, and HL.60
Blast cells (24), a subclone ofthe HL-60 cell line, were generous gifts ofDr. R.
Gallo of the National Cancer Institute, Bethesda, MD, and Dr. P. Majors,
Harvard Medical School, Boston, MA, respectively.
Media and Culture Conditions:
￿
Thecells were cultured in mini-
mal essential medium-alpha supplemented with 10% fetal bovine serum, 100
U/ml penicillin, and 100 gg/ml streptomycin. Media and sera were obtained
from Grand Island Biological Co. (Grand Island, NY). Antibiotics were pur-
chased from Eli Lilly Co. (Indianapolis, IN). Cells were grown at 37°C in a
humidified 95% air-5% CO2 atmosphere. Cells were subcultured twice weekly
at a seeding density of 2 x 10' cells/ml for the HL-60 cell line and 1 x 10'
cells/ml for the HL.60 Blast line. Tissue culture plastics were obtained from
Costar, Data Packaging (Cambridge, MA).
Assessment of Cell Growth:
￿
Toexaminetheeffectsof 1,25(OH)2D3
on cell growth, 5 ml ofcells at 10' cells/ml were seeded in 25-cm' flasks. Cells
were seeded in thepresence ofvarious concentrations of 1,25(OH)2D3 in culture
medium supplemented with 10% fetal bovine serum. Control cultures con-
tained the ethanol vehicle at 0.1 % (vol/vol). After shaking to loosen any
adherent cells, 100 pl ofeach cell culture were removed every 24 hfor 4 dand
cells were counted with a hemacytometer. Cell viability was determined via
trypan blue exclusion.
(3H]FMLP Binding:
￿
This assay was performed as described elsewhere
(25), with modifications. Briefly, cells were seeded at 10' cells/ml in medium
containing either varying concentrations of 1,25(OH)2D3 or 10-6 M RA, a
combination ofboth, 1% DMSO (vol/vol) as apositive control, or the ethanol
vehicle alone. Cells were cultured for 6 d in the presence of the various
differentiation-inducing compounds. On the sixth day, the cells were harvested
by centrifugation and washed in PBS. 1 x 10' cells in 1 ml ofPBSwere mixed
in microfuge tubes with ['HJFMLP at afinal concentration of 2.9 x 10-9 M.
DMSO (0.1% final) or unlabeled FMLP (2.9 x 10-6 M final) was added to
each tube. Cells were incubated with shaking every 5 min at 4°C for 1 h, then
sedimented by centrifugation in an Eppendorf microfuge for 30 s. The super-
natant was discardedandthepelletswere washed once in PBS. Thesupernatant
was discarded, and the pellet was dissolved in 1 ml of Ready-Soly HP/b
(Beckman Instruments, Irvine, CA) and counted in a Beckman liquid scintil-
lation counter. The difference in counts between samples with DMSO alone
and those with excess unlabeled FMLP was defined as specific FMLP binding.
Cell Maturation: The HL-60 cells were cultured with or without
1,25(OH)2D3 in medium (Flow Laboratories, Inc., Rockville, MD)containing
10% fetal calf serum, as described above. Cytocentrifuge preparations were
made andthe histochemical stains, Wright-Giemsa and nonspecific acid ester-
ase, were used to help determine cell lineage (26, 27). Nonspecific acid esterase
activity was determined by the ability of cells to hydrolyze a-naphthyl acetate
and/or a-naphthyl butyrate.
PhagoCytoSis:
￿
The method developed for studying phagocytosis has
been described in detail (28). Briefly, Candida albicans were opsonized in 20%
human AB serum, anda 5:1 ratio of Candida to leukemic cells was incubated
at 37°C for 30 min. After the incubation, the solution of the heat-killed
opsonized Candida and leukemia cells was placed in trypan-eosin stain to
confirmthat the Candida had been phagocytizedandwere not merely adherent
to the cell surface. Heat-killed Candida must be completely ingested to be
protected from taking up the stain. The values obtained with this assay
concurred with those using the Giemsa-staining technique (29).
NBT Reduction:
￿
The reduction of NBT was measured qualitatively.
1 ml of cells (2 x 106 cells/ml) was suspended in amedium containing 20%
fetal calfserum, NBT(2%, dissolvedin PBS), and200 ng offreshly diluted 12-
O-tetradecanoyl phorbol-13-acetate. Thecellsuspension was incubated at 37°C
for20 min, washed three times in cold PBS, cytocentrifuged, fixed in methanol,
and stained 5 minwith safranin (30, 31). The percentage of cells containing
intracellular reduced blue-black formazan deposits was determined through
light microscopy by differentially counting 200 cells.
Nuclear Extract Preparation:
￿
Atleast300 X 101 cellswereharvested
in logarithmic growth, rinsed in fresh medium and resuspended in 10 ml of
1 % fetal bovine serum in minimal essential medium-alpha. Cells were then
labeled with 5 nM 1,25(OH)2['H]D3 for 2 hat 37°C in ashaking water-bath.
Thefollowing manipulations were done at 4°C. Cells were rinsed three times
in ice-cold PBS with I %bovine serum albumin, followed by centrifugation at
500 gfor 5 min. The resulting pellet wasresuspended in 5 ml of0.01 M Tris-
HCI, pH 7.5, 2 mM EDTA, 0.5 mM EGTA, 0.15 mM spermine, 0.5 mM
spermidine, and 5 mM dithiothreitol and, after a 20-min incubation, the cells
were lysed by Dounce homogenization. Thelysate wascentrifuged again for 15min at 1,100 g, and the pellet was resuspended in 3 ml of KET-0.3 and
centrifuged again for 5 min at 12,000 g after a 30-min incubation. This high
salt extraction (0.3 MKCl) was used to recover the hormone-receptorcomplex
from the nucleus (32). The supernatant from this extract was then used as
described for DNA-cellulose chromatography or sedimentation analysis.
DNA-Cellulose Chromatography:
￿
DNA-cellulose chromatogra-
phy was performed as outlined elsewhere (33). Briefly, 1 ml of the nuclear
extract was diluted with 5 vol (vol/vol) ofKET-0 to reduce ionic strength, and
applied to a 10-ml DNA-cellulose column equilibrated with KET-0.05. After
washing with KET-0.05, the labeled receptor complex was eluted with a 100-
ml KET-0.05-0.5 linear gradient. All operations were performed at 4°C. 3-ml
fractions were collected (flow rate = 1 ml/min), anda 0.5-ml aliquot of each
fraction wascounted in 5 ml ofa liquifluor-based aqueous scintillation cocktail
(33% efficiency) in a Beckman scintillation counter. Salt concentrations were
determined with aconductivity meter (Radiometer, Copenhagen, Denmark).
Sedimentation Analysis:
￿
From the nuclear extract, 300-Al aliquots
were incubated for 4 hat 4°C with one ofthe following: 8 Al of KET-0.3 plus
20 gl offresh hybridoma culture medium; 8 pl of KET-0.3 plus 20 yl of SP2/
0-4A5 clonal medium containing the anti-1,25(OH)2D3-receptor monoclonal
antibody 4A5,y (34); or 100 Kl of SP2/0-8D3 clonal medium containing the
anti-1,25(OH)2D3-receptor monoclonal antibody 8D3Á (34). A 300-,ul aliquot
of nuclear extract was also incubated for 0.5 h at 4°C with 100 Al of 10 mM
PCMBS in KET-0.3, pH 7.4. Each 400-Al incubate was layered onto a 4.6-ml
gradient of 10-30% sucrose prepared in KET-0.3 with ultrapure sucrose using
a Buchler gradient maker and Auto-Densi Flow apparatus. Thegradients were
then centrifuged at 2°C in an SW 50.1 rotor (Beckman Instruments, Inc.) at
265,000 g for 18 h. Four-drop fractions were collected from the top using a
Gilson fractionator and counted in 5 ml of scintillation cocktail.
Saturation Analysis: At least 200 x 106 cells were harvested in
logarithmic growth, washed two times with PBS, and resuspended in minimal
essential medium-alpha containing 10% fetal bovine serum at 2 x 10' cells/
ml. Aliquots of 0.5 ml (10' cells total) then were incubated for 4 h with
1,25(OH)2['H]D3 at concentrations of0.5 nM, 1 .0 nM, 2.0 nM, 5.0 nM, and
10.0 nM ± 100-fold excess nonradioactive 1,25(OH)2D3. All incubations were
carried out in duplicate at 37°C in a shaking water-bath. All subsequent
operations were performed at 4°C. At the end ofthe incubation, the cells were
rinsed twice with ice-cold I% bovine serum albumin in PBS and once with
PBSalone, each followed by centrifugation for 5 minat 700 g. Each pellet was
resuspended and lysed in 0.5 ml of 0.3 M KCl plus 5 mM DTTplus 0.5%
Triton X-100 in 0.01 MTris-HCI, pH 7.5, 2 mM EDTA, 0.5 mM EGTA, 0. 15
mM spermine, 0.5 mM spermidine, and 5 mM dithiothreitol for 30 minwith
intermittent vortexing. Thelysate wascentrifuged for 10 minat 35,000 g, the
supernatant was recovered, diluted in 6 vol (vol/vol) of 10 mM Tris-HCI in
I% Triton X-100, pH 7.4, and filtered through two 2.5-cm WhatmanDE-81
filters via gravity (no applied suction) as originally described by Santi et al.
(35). Each assay tube was rinsed twice morewith 10 mM Tris in l % Triton X-
100, pH 7.4 to insure a quantitative yield. The filters were transferred to
scintillation vials, dried in acetone, and counted for tritium in 5 ml of scintil-
lation cocktail.
RESULTS
Growth Response Studies
HL-60 cells showed a time-dependent, biphasic dose re-
sponse when grown with added 1,25(OH)2D3 (Fig. 1A). Sig-
nificant inhibition of growth could be seen as low as 10-R M
1,25(OH)2D3 and, within 4 d at 10' M, growth was slowed
to <40% of control. However, a significant stimulation in
growth above the control occurred as HL-60 cells were cul-
tured with 10-9 M 1,25(OH)2D3 (Fig. IA). At concentrations
of 10-10_10-'2 M 1,25(OH)2D3 the growth of HL-60 cells
remained unaffected (data not shown). To verify the validity
of this biphasic response, we repeated the experiment twice,
with the same results (data not shown). Contrary to HL-60,
the HL-60 Blast cells showed no growth response to
1,25(OH)2D3 at any concentration tested (Fig. 1 B).
Functional and Morphological Studies
Table I represents the 1,25(OH)2D3 dose responsiveness of
HL-60 and HL-60 Blast cells to undergo various functional
and morphological changes indicative of differentiating mye-
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FIGURE I Dose-responsive growth of (A) HL-60 and (B) HL-60
Blast cells in 1,25(OH)2D3. Cells were inoculated at 105 cells/ml in
triplicate flasks on day 0 in the presence of various concentrations
of 1,25(OH)2D3. At the times indicated, each flask was sterilely
sampled and counted as described in Materials and Methods.
Cell viability was >99%. Control (0.1% ethanol), (O); 10' M
1,25(OH)2D3, ("); 10-8 M 1,25(OH)2D3, ("); 10-9 M 1,25(OH)2D3,
("). Each point represents the mean of triplicate counts (± standard
deviation). In A all points for the day-3 and day-4 time points are
significantly different from one another as statistically evaluated by
the Student's t-test (P < 0.05). In addition, the difference between
10' M and 10-a M 1,25(OH)2D3-exposed HL-60 cells at the day-2
time point represents the same statistical significance (P < 0.05).
loid cells. Untreated HL-60 cells undergo little spontaneom
differentiation (1-2%) as assayed by morphology, NBT re-
duction, phagocytic and nonspecific acid esterase activity.
After 7 d of treatment with 10-11 M 1,25(OH)2D3, significant
differentiation occurred, as measured by the four test param-
eters. As the most sensitive assessment of differentiation, the
NBT reduction assay demonstrated significant differentiation
occurring at as low as 10-" M 1,25(OH)2D3. Phagocytosis
exhibited the least response to 1,25(OH)2D3 induction (Table
I). Surprisingly, we also noticed that the HL-60 cellsexposed
to 1,25(OH)2D3 became adherent to plastic, a characteristic
of macrophages and not of granulocytes. Because this was in
contrast to the 1,25(OH)2D3-induced granulocytic differentia-
tion reported by Miyaura et al. (4), we were prompted to
investigate this phenomenon further. Of particular interest
was that strong nonspecific acid esterase activity was induced
in the HL-60 cells exposed to 1,25(OH)2D3. Nearly all the
HL-60 cellsdeveloped intense nonspecific acid esterase activ-
ity with exposure to 10-6 M 1,25(OH)2D3. Nonspecific acid
esterase activity is present in normal monocytes and macro-
phages, but not in neutrophils. Morphologically, the mature
cells were -13-15 AM in diameter; the nuclei were either
large with an indented contour and delicate chromatin or
reniform with a moderately densechromatin. The cytoplasm
was abundant, grayish in color, and contained few granules.
Morphologically, the cells acquire characteristics ofboth mon-
ocytes and metamyelocytes. All mature-appearing cells were,
however, nonspecific acid esterase-positive and none resem-
bled mature granulocytes. The HL-60 cells began to show
significant functional changes as early as 1 d after beginning
treatment with 1,25(OH)2D3 (data not shown). The percent-
age of differentiated cellsincreased in a dose-dependent man-
ner, with concentrations as high as 10-6 M 1,25(OH)2D3
causing >70% ofthe cells to demonstrate morphological and
functional properties ofdifferentiated cells. At this concentra-
tion, 60% of the cells became phagocytic. The HL-60 Blast
cells were unresponsive at all 1,25(OH)2D3 concentrations
(Table 1).
MANGELSDORF ET AL.
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Functional and Morphological Changesin HL-60 and HL-60 Blast Cells Induced by Various Concentrations of 1,25(OH)2D 3*
[3H]FMLP Binding Studies
Morphology
* HL-60 and HL-60 Blast cells were cultured in the presence or absence of various concentrations of 1,25(OH)2D3 as detailed in Materials andMethods. After
7 d, cells were assessed for the various differentiation parameters. Cell viability was >99%. All data are expressed as the percentage of total cells assayed. At
least 200 cells were assessed for each parameter. The HL-60 cell data represent the mean t standard deviation of triplicate assays.
R Basal 1,25(OH),D, in 10%fetal bovine serum is 1 .6 x 10-" M.
s Intermediate to mature cells include monocytes and macrophages.
Represents the average of two experiments.
To better understand the 1,25(OH)2D3 induction process,
we cultured the HL-60 cells with either 10' or 10-8 M
1,25(OH)2D3 for varying time periods, washed the cells, and
assessed the ability of HL-60 cellsto differentiate aftera total
of 7 d. Table II shows that morphological and functional
changes begin to be minimally expressed after 7 d with a
1,25(OH)2D3 incubation as short as 18 h. The differentiation
response becomes more pronounced the longer the hormone
remains in the culture medium. These results suggest that the
presence of 1,25(OH)2D3 is required and must be maintained
over a long period of time relative to temporal events occur-
ring at the molecular level.
To develop a dose-dependent biochemical marker of in-
duced HL-60 differentiation, we used a modification of the
['H]FMLP binding assay developed by Nelson et al. (36).
Previous investigators have shown that development of chem-
otaxis coincides with the appearance of specific [3H]FMLP
binding in the DMSO-induced differentiated state of HL-60
cells (25). Fig. 2 shows the results of specific [3H]FMLP
binding to HL-60 cells after 6 d of treatment with various
inducers ofdifferentiation. Specific [3H]FMLP binding in cells
exposed to the various compounds was contrasted to specific
['H]FMLP binding in unexposed control cells (see Fig. 2,
inset). When treated with 1,25(OH)2D3, HL-60 cells re-
sponded in a dose-dependent manner. A maximal effect was
seen at 10' M 1,25(OH)2D3 and binding decreased in a
sigmoidal fashion (Fig. 3) until there was no detectable effect
at 10-'0 M. The effective dose at which 50% ofspecific [3H]-
394
￿
THE )OURNAL OF CELL BIOLOGY " VOLUME 98, 1984
FMLP binding can be induced (EDso) was estimated to be 5 .7
nM (Fig. 3). Strikingly, the EDso for 1,25(OH)2D3-provoked
NBT reduction (Table 1) coincided with this value when
plotted together with the FMLP binding data as shown in Fig.
3.
In comparison to 1,25(OH)2D3-induced cells, 1 % DMSO-
treated HL-60 cells produced a response similar to that with
10-9 M 1,25(OH)2D3 (Fig. 2). RA, a known inducer of HL-
60 differentiation as measured by morphology and NBT
reduction at micromolar amounts (37), did not induce [3H]-
FMLP binding at 10-6 M (Fig. 2). We also evaluated the
ability of suboptimal doses of 1,25(OH)2[3H]D3 and RA in
concert to stimulate specific [3H]FMLP binding in HL-60
cells. No synergistic response was detected at 10-'0 M
1,25(OH)2D3 and 10-6 M RA together (Fig. 2). This evidence
suggests that 1,25(OH)2D3-induced differentiation may be
occurring through a mechanism separate from that of RA-
induced differentiation. Unsurprisingly, the HL-60 Blast cells
were unresponsive to induction ofspecific ['H]FMLP binding
when challenged with 10`8 M 1,25(OH)2D3 (Fig. 2).
Detection and Quantitation of 1,25(OH)2D3
Receptors
To approach the mechanism whereby 1,25(OH)2D3induces
differentiation in HL-60 cells, we first attempted to determine
whether 1,25(OH)2D3 receptors were present in these cells.
Aliquots ofhigh salt nuclearextracts, prepared by first labeling
intact HL-60 and HL-60 Blast cells with 1,25(OH)2D3 (see
Materials and Methods), were analyzed by high salt sucrose
density gradient centrifugation. As illustrated in Fig. 4A,
Added
concentration of
1,25(OH)2D3=
M
Cell line NBT reduction
%
Phagocytic cells
%
Myeloblasts and
promyeloblasts
%
Intermediates
to mature
%
Nonspecific
acids
esterase-
positive
HL-60 2±3 2f2 99 t2 1±2 2 0
HL-60 Blast 0 1 100 0 0
10-"
HL-60 10±2 2±3 95±3 5±4 3
HL-60 Blast 0 0 100 0 0
10-10 HL-60 18±11 13±7 82±5 18±7 10
HL-60 Blast 0 0 100 0 0
10-9
HL-60 37±19 20±7 66±9 34±6 25
HL-60 Blast 0 0 100 0 0
10-8
HL-60 64 ± 13 26 ± 4 45 ± 12 55 ± 9 54
HL-60 Blast 0 0 100 0 0
10-'
HL-60 82±8 44±9 32±5 67±6 82
HL-60 Blast 3 5 96 4 0
10-6
HL-60 86 ± 12 60 ± 3 27 ± 6 78 ± 14 98
HL-60 Blast 1 0 100 0 0Functional and Morphological Changes in HL-60 Cells Exposed
to 1,25(OH)2D3 for Various Time Periods*
TABLE II
HL-60 cells were cultured as detailed in Materials and Methods in the
presence of 10-7 M or 10-° M 1,25(OH)2D3 for various time periods. At the
end of each time period, cells were washed free of 1,25(OH)2D3-supple-
mented medium, resuspended in fresh medium, and allowed to continue
growing up to 7 d total. On d 7, cells were assessed for the various
differentiation parameters. Cell viability was >99%. All data are expressed
as the percentage oftotal cells assayed. At least 200cells were assessed for
each parameter.
Blast cells include myeloblasts and promyeloblasts.
Intermediate to mature cells include monocytes and macrophages.
virtually all ofthe bound 1,25(OH)2[3H]D3 migrates in a single
3.3S peak, characteristic of 1,25(OH)2D3 receptors (12, 14,
33). This peak is completely obliterated by the mercurial
reagent, PCMBS (Fig. 4A), indicating dissociation of the
1,25(OH)2D3hormone-receptor complex (38). Finally, to con-
firm the 3.3S macromolecule as the 1,25(OH)2D3 receptor,
monoclonal antibodies to the 1,25(OH)2D3 receptor were
incubated with the nuclear extract before sedimentation. As
anticipated, the monoclonal antibody 4A5y shifted the mi-
gration of the 3.3S macromolecule to the 7-8S position (Fig.
4A), a finding consistent with the sedimentation properties of
the hormone-receptor-antibody complex (34). This observa-
tion represents unequivocal identification, in that the 4A5y
monoclonal antibody has been shown to interact with
1,25(OH)2D3 receptors from all sources tested, including hu-
man cells(34). In contrast, the 8D3g monoclonal antibody is
specific for chick intestinal receptor (34), and therefore has
no effect on the sedimentation of this 3.3S macromolecule
(Fig. 4A).
Fig. 4B shows a similar sedimentation pattern for the
nuclear extract derived from HIr60 Blast. A PCMBS-disso-
ciable 3.3S macromolecule that can be recognized by 4A5y
(but not 8D3u) antibody demonstrates the presence ofa small,
yet detectable, amount of 1,25(OH)2D3 receptor in HL-60
Blast cells.
Using the 1,25(OH)2D3 receptor's inherent DNA-cellulose
binding ability (12, 33), we chromatographically analyzed
aliquots of the same nuclear extracts used in the sucrose
density gradient centrifugation experiments. Fig. 5A illus-
trates the presence of an HL-60 1,25(OH)2D3-binding com-
ponent that adsorbs to DNA under low ionic strength and
elutes at a concentration of0.23 M KCI. This elution pattern
is, in part, characteristic ofthe 1,25(OH)2D3 receptor (33). A
smaller receptor-like peak of weaker DNA binding elutes at
0.13 M KCI, and is at present not identified. Since there is no
evidence on the sucrose gradients of a second peak of radio-
activity, or ofone that is unreactive to PCMBS or monoclonal
antibody (Fig. 4A), this smaller peak may represent a prote-
olytic form of the receptor with altered DNA binding. Inte-
grated analysis of these DNA-binding peaks yielded a
1,25(OH)2D3 receptor value of0.28 pmol/10' cells.
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FIGURE 2
￿
Specific [3H]FMLP binding in HL-60 cells treated with
various differentiation-inducing compounds. Each histogram rep-
resents the difference in [3H]FMLP binding between treated and
untreated control cells. The inset illustrates a typical experiment
used to derive specific binding in HL-60 cells induced by 10-' M
1,25(OH)2D3. Untreated (0.1%ethanol control) or treated cells were
incubated with tritiated FMLP in the absence (A) or presence (B) of
1,000-fold excess radioinert FMLP. The data represent the mean ±
standard deviation of triplicate assays. The difference betweentotal
(A) and nonspecific (B) [3H]FMLP binding of the control cells was
subtracted from the difference between total (A) and nonspecific
(B) [3H]FMLP binding of the treated cells and expressed in this
Figure as induced specific [3H]FMLP binding.
FIGURE 3 Dose response curves of 1,25(OH)2D3-induced differ-
entiation events in HL-60 cells. The data are expressed as percent
induced response at various concentrations of 1,25(OH)2D3 and
derived from Table I (NBT reduction) and Fig. 2([3H]FMLP binding).
It is assumed that all cells have the potential to eventually differ-
entiate and reduce NBT. Cells showing specific [3H]FMLP binding
(O); cells showing reduction of NBT ("); effective dose for a 50%
induced differentiation response (x).
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FIGURE 4 Sucrose density gradient analysis of 1,25(OH)2[3H]D3
binding in nuclear extracts of HL-60 (A) and HL-60 Blast (B) cells.
10-30% sucrose density gradient ultracentrifugation was performed
as outlined in Materials and Methods. Previous to u[tracentrifuga-
tion, samples were incubated in the presence (O) or absence (") of
PCMBS, the presence of 4A5y monoclonal antibody (A), or the
presence of 8D3ju monoclonal antibody (o). Sedimentation markers
were based on previously described analysis (34).
Fraction
FIGURE 5 DNA-cellulose chromatography of 1,25(OH)2[3H]D3
binding in nuclear extracts of HL-60 (A) and HL-60 blast (B) cells.
Chromatography was performed as described in Materials and
Methods. After samples were applied to DNA-cellulose columns,
fall-through radioactivity was monitored until a consistent baseline
was established. DNA-binding components were then eluted with
linear salt gradients and counted for radioactivity.
Fig. 5B shows that HL-60 Blast also contains a small, but
measurable, amount of 1,25(OH)2D3 binding component that
elutes at 0.23 M KCI. This peak corresponds to 0.023 pmol
of apparently functional 1,25(OH)2D3 receptor/108 cells.
To provide insight into the role of the receptor in the
mechanism of action of 1,25(OH)2D3-induced differentiation,
we sought to measure the specific uptake of 1,25(OH)2[3H]D3
into intact HL-60 cells under conditions that are normally
used to grow these cells in culture. Cells were monitored for
the specific uptake of various concentrations of 1,25(OH)2-
[3H]D3 in the presence of 10% fetal bovine serum in medium
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FIGURE 6
￿
Determination of the equilibrium dissociation constant
of 1,25(OH)2[3H]D3 internalization in intact HL-60 cells. Saturation
analysis (A) was determined by incubating intact cells under normal
growth conditions for 4 h with 10% serum along with various
concentrations of tritiated 1,25(OH)2D3 in the presence (A) or
absence (O) of 100-fold excess nonradioactive 1,25(OH)2D3. Spe-
cific binding (O) was transformed by Scatchard analysis and then
the data line-fitted by linear regression. (B) to yield a KIt = 5.4 nM
(abscissa intercept = 4,000 molecules/cell, r = -0.71).
and assayed on DEAE filters as described in Materials and
Methods. Fig. 6A demonstrates that uptake by intact HL-60
cellsis a specific and saturable process. Accordingly, Scatchard
transformation of these data yields an equilibrium dissocia-
tion constant for 1,25(OH)2D3 internalization (K,t) of 5.4 nM
(Fig. 6B), and extrapolation to the abscissa predicts 4,000
1,25(OH)2D3 receptors molecules per HL-60 cell. The Kit
(5.4 nM) is virtually identical to the ED50 (5.7 nM) for
induction of specific [3H]FMLP-binding and NBT reduction
(Fig. 3).
DISCUSSION
Recently, Miyaura et al. and Abe et al. (4, 5) made the
important observation that myeloid leukemia cells differen-
tiatewhen challenged with the hormonal form of vitamin D3,
namely 1,25(OH)2D3. This observation, coupled with the
emergence of a wide variety of nontraditional target cells for
1,25(OH)2D3 (14, 39), suggests that 1,25(OH)2D3 may play a
more fundamental role than previously appreciated. In the
present communication, we report biologicaland biochemical
characterization ofthe potent effectof 1,25(OH)2D3 in causing
the differentiation of human promyelocytic leukemia (HL-
60) cells.
Physiologic levels of 1,25(OH)2D3 in the culture medium
of HL-60 cells induced the maturation of the cells as evi-
denced by their ability to reduce NBT (Table I, Fig. 3), by the
appearance of receptor-like binding of the chemoattractant
FMLP (Figs. 2 and 3), and by the inability to phagocytose
Candida after 7 d exposure to 1,25(OH)2D3 (Table I). In
contrast to the data of others (4, 19, 40), we provide convinc-
ing evidence that HL-60 cellsare differentiating toward mon-
ocytes and macrophages after exposure to 1,25(OH)2D3. In a
preliminary abstract, Bar-Shavit et al. (20) suggested that
1,25(OH)2D3-induced HL-60 cells became adherent to plastic
and that these adherent cells were capable of effective cell-
bone attachment and degradation, all properties ofosteoclast-
related monocytes and macrophages. The role of 1,25(OH)2D3
and the regulation of macrophage function is not without
precedent. In a separate report Bar-Shavit et al. (41) have
shown that the impaired phagocytic response of peritoneal
macrophages from vitamin D3-deficient mice can be corrected
by 1,25(OH)2D3. Interestingly, Miyaura et al. (4) observed
that 1,25(OH)2D3-exposed HL-60 cells become adherent toplastic; however, they report all of these cellsto be in various
stages of granulocytic differentiation and none in the macro-
phage lineage. In addition to their becoming adherent to
plastic, we show that the differentiated cells are strongly
nonspecific acid esterase-positive (Table I). This enzyme is
present in normal monocytes and macrophages, but not in
granulocytes. Morphologically, most of the cells look like
monocytes/macrophages and a lower percentage appear to
have characteristics of metamyelocytes, but none of the cells
resemble mature granulocytes. It is well established that HL-
60 can be induced to macrophages after exposure to 10-'-
10-8 M 12-O-tetradecanoyl phorbol-13-acetate (42, 43). As-
suming that normal myeloid cellscan be stimulated to differ-
entiate into monocytes/macrophages by 1,25(OH)2D3, this
sequence could comprise an important mechanism whereby
1,25(OH)2D3 enhances bone resorption, in vivo. This would
occur because monocytes can directly resorb bone mineral
and because they are apparent precursors of bone-resorbing
osteoclasts. HL-60 is likely a good model system to test this
hypothesis.
The induction of membrane glycoproteins and receptors
often comprises a key terminal step in cell differentiation.
Recently, investigators showed that HL-60 cells increased the
number of insulin receptors when induced to differentiate
with 1,25(OH)2D3, RA, DMSO, and 12-O-tetradecanoylphor-
bol-l3-acetate (40). A second membrane receptor, that for
the N-formyl peptides, has been shown to be enhanced by
DMSO treatment of HL-60 cells (25). The binding affinities
for a series of N-formyl oligopeptides to receptors on the
surface of human neutrophils correlates with their chemotac-
tic potencies (44), indicating that there is a relationship be-
tween membrane receptors for theN-formyl peptides and the
development ofthe chemotactic response. Although our data
do not reflect conclusive changes in FMLP receptor number
or binding affinities, the appearance of [3H]FMLP binding
can be used as a measure ofthe maturationofthe chemotactic
response in HL-60 cells exposed to 1,25(OH)2D3. We have
found that 1,25(OH)2D3 is a more powerful inducer of [3H]-
FMLP binding than 1 % DMSO in HL-60 cells (Fig. 3),
intimating that 1 ;25(OH)2D3 is extremely effective in creating
motile behavior in myeloid leukemia cells. Surprisingly, RA,
which like DMSO triggers granulocytic differentiation ofHL-
60 cells (37), did not increase [3H]FMLP binding (Fig. 2). We
have no explanation for this paradox, although the HL-60
cells we used do not display striking morphologic differentia-
tion in the presence of RA and lack the cellular retinoid-
binding protein (45).
At present a critical question regarding control of matura-
tion of HL-60 cellsby 1,25(OH)2D3 is the molecular mecha-
nism underlying this hormone-induced differentiation proc-
ess. Tanaka et al. (19) have provided preliminary evidence
that 1,25(OH)2D3 functions in HL-60 cells via a steroid hor-
mone-receptor mechanism by showing that the rank order of
potency of various vitamin D3 metabolites in inducing HL-
60 differentiation corresponded with the relative ability of
these metabolites to compete with 1,25(OH) 2D3 for binding
to a putative cytosol receptor. In the present work, we une-
quivocally characterized 1,25(OH)2D3 receptors in HL-60
cellsafterexposing intact cellsto 1,25(OH)2D3 in the presence
ofserum. Using this technique, we identifiedthe 1,25(OH) 2D3
receptor by sucrose density gradients (Fig. 4), DNA cellulose
chromatography (Fig. 5), selective chemical dissociation with
PCMBS (Fig. 4), and specific immunochemical reactivitywith
monoclonal antibody (Fig. 4). The above intact cell labeling
procedure also allows the determination of the true kinetics
of 1,25(OH)2D3 binding (i.e., Kim) that would be expected to
occurin the bioresponse experiments. Thus, for the first time,
binding and bioresponse data are comparable and the result
is that the Kim of 1,25(OH)2D3 in HL-60 at 4 h of incubation
is coincident with the ED5o for the biological effects of the
hormone on this cell at 6-7 d (Figs. 3 and 6). The fact that
nuclear binding of receptor is a rapid event, whereas differ-
entiation requires several days, may be reconciled by propos-
ing that the 1,25(OH)2D3 receptor must be maintained at
some steady-state level within the nucleus over the long term.
This then provides strong evidence for a correlation between
events initiated by the 1,25(OH)2D3 receptor and the cellular
bioresponsesto 1,25(OH)2D3. As ancillary support to receptor
mediation of these events we have found that the HL-60
subclone, HL-60 Blast, is not only insensitive to 1,25(OH) 2D3-
induced differentiation (Figs. 1 and 2, Table I) but also has a
much reduced 1,25(OH)2D3 receptor copy number (8% ofthe
parent line [Fig. 5]). It is therefore tempting to speculate that
the differentiation process requires the presence of a critical
concentration of 1,25(OH)2D3 receptors. However, because
HL-60 Blast cells have not responded to any tested inducer
thus far, an equally plausible explanation is that these cells
have simply lost their ability to differentiate.
In conclusion, HL-60 represents a cell line that possesses
aggressive malignant proliferative potential in vivo but differ-
entiates terminally when challenged with agents such as
1,25(OH)2D3, in vitro. Possibly, the assays ofthe 1,25(OH)2D3
receptor in peripheral leukocytes from patients with acute
promyelocytic leukemia, or even preleukemic conditions,
may be predictive of the ultimate response of the patient to
adjunct therapy with exogenous 1,25(OH)2D3. Promising re-
sults have already been obtained in the survival of mice
inoculated with M-1 leukemic cells (6). Clearly, both an
understanding of the mode of action of 1,25(OH)2D3 in
mediating the differentiation ofhematopoietic cells and a test
of its clinical effectiveness in leukemia are significant prob-
lems for the immediate future.
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